Primary Hypercholesterolaemia and Mixed Dyslipidaemia
1 clinical trials · Condition
◉ Watch Primary Hypercholesterolaemia and Mixed Dyslipidaemia
| Record | Firm | Date |
|---|---|---|
| Non-interventional Study on the Monthly Administration of 300 mg AliRocumab (PRALUENT®) With the 2 ml SYDNEY Auto-injector (NCT05129241) | Sanofi | 2021-11-18 |
Track Primary Hypercholesterolaemia and Mixed Dyslipidaemia automatically
Every clearance here is in the API, with alerts when new ones post.